Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Predictors of LDL-cholesterol target value attainment differ in acute and chronic coronary heart disease patients: Results from DYSIS II Europe.

Ferrieres J, De Ferrari GM, Hermans MP, Elisaf M, Toth PP, Horack M, Brudi P, Lautsch D, Bash LD, Baxter CA, Ashton V, Ambegaonkar B, Gitt AK.

Eur J Prev Cardiol. 2018 Oct 18:2047487318806359. doi: 10.1177/2047487318806359. [Epub ahead of print]

PMID:
30335504
2.

Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy.

Lorenzi M, Ambegaonkar B, Baxter CA, Jansen J, Zoratti MJ, Davies G.

Clin Res Cardiol. 2018 Oct 9. doi: 10.1007/s00392-018-1379-z. [Epub ahead of print]

PMID:
30302558
3.

Low-density lipoprotein cholesterol target attainment in patients with stable or acute coronary heart disease in the Asia-Pacific region: results from the Dyslipidemia International Study II.

Poh KK, Ambegaonkar B, Baxter CA, Brudi P, Buddhari W, Chiang FT, Horack M, Jang Y, Johnson B, Lautsch D, Sawhney J, Vyas A, Yan BP, Gitt AK.

Eur J Prev Cardiol. 2018 Sep 10:2047487318798927. doi: 10.1177/2047487318798927. [Epub ahead of print]

PMID:
30198749
4.

Prevalence of lipid abnormalities and cholesterol target value attainment in Egyptian patients presenting with an acute coronary syndrome.

Sobhy M, El Etriby A, El Nashar A, Wajih S, Horack M, Brudi P, Lautsch D, Ambegaonkar B, Vyas A, Gitt AK.

Egypt Heart J. 2018 Sep;70(3):129-134. doi: 10.1016/j.ehj.2018.05.001. Epub 2018 Aug 22.

5.

Do acute coronary events affect lipid management and cholesterol goal attainment in Germany? : Results from the Dyslipidemia International study II.

Gitt AK, Rieber J, Hambrecht R, Brachmann J, Graf K, Horack M, Karmann B, Vyas A, Lautsch D, Ambegaonkar B, Brudi P.

Wien Klin Wochenschr. 2018 Sep 3. doi: 10.1007/s00508-018-1375-3. [Epub ahead of print]

PMID:
30178071
6.

Prevalence of lipid abnormalities and cholesterol target value attainment in patients with stable coronary heart disease or an acute coronary syndrome in Saudi Arabia.

Al Sifri S, Al Shammeri O, Al Jaser S, Alkhenizan A, Bin Shafi Shafiurrehman A, Morcos B, Wajih S, Elnahal I, Horack M, Brudi P, Lautsch D, Ambegaonkar B, Vyas A, Baxter CA, Gitt AK.

Saudi Med J. 2018 Jul;39(7):697-704. doi: 10.15537/smj.2018.7.22146.

7.

Real-World, Multinational, Retrospective Observational Survey of the ADAS-Cog and Associations with Healthcare Resource Utilization in Patients with Alzheimer's Disease.

Ritchie CW, Khandker RK, Pike J, Black CM, Jones E, Ambegaonkar BM.

J Alzheimers Dis. 2018;64(3):899-910. doi: 10.3233/JAD-180306.

PMID:
29966202
8.

Use of guideline-recommended management in established coronary heart disease in the observational DYSIS II study.

Ferrières J, Lautsch D, Ambegaonkar BM, De Ferrari GM, Vyas A, Baxter CA, Bash LD, Velkovski-Rouyer M, Horack M, Almahmeed W, Chiang FT, Poh KK, Elisaf M, Brudi P, Gitt AK.

Int J Cardiol. 2018 Nov 1;270:21-27. doi: 10.1016/j.ijcard.2018.06.008. Epub 2018 Jun 6.

9.

Contemporary data on treatment practices for low-density lipoprotein cholesterol in 6794 patients with stable coronary heart disease across the world.

Gitt AK, Lautsch D, Ferrières J, De Ferrari GM, Vyas A, Baxter CA, Bash LD, Ashton V, Horack M, Almahmeed W, Chiang FT, Poh KK, Brudi P, Ambegaonkar B.

Data Brief. 2018 May 1;18:1937-1940. doi: 10.1016/j.dib.2018.04.092. eCollection 2018 Jun.

10.

Body mass index impacts the choice of lipid-lowering treatment with no correlation to blood cholesterol - Findings from 52 916 patients in the Dyslipidemia International Study (DYSIS).

Ferrières J, Lautsch D, Gitt AK, De Ferrari G, Toplak H, Elisaf M, Drexel H, Horack M, Baxter C, Ambegaonkar B, Brudi P, Toth PP.

Diabetes Obes Metab. 2018 Nov;20(11):2670-2674. doi: 10.1111/dom.13415. Epub 2018 Jul 10.

PMID:
29888459
11.

Low-density lipoprotein cholesterol target achievement in patients surviving an acute coronary syndrome in Hong Kong and Taiwan - findings from the Dyslipidemia International Study II.

Yan BP, Chiang FT, Ambegaonkar B, Brudi P, Horack M, Lautsch D, Vyas A, Gitt AK.

Int J Cardiol. 2018 Aug 15;265:1-5. doi: 10.1016/j.ijcard.2018.01.099.

PMID:
29885676
12.

Analysis of Episodes of Care in Medicare Beneficiaries Newly Diagnosed with Alzheimer's Disease.

Khandker RK, Black CM, Xie L, Kariburyo MF, Ambegaonkar BM, Baser O, Yuce H, Fillit H.

J Am Geriatr Soc. 2018 May;66(5):864-870. doi: 10.1111/jgs.15281. Epub 2018 Mar 30.

PMID:
29601083
13.

Quantifying the Diagnostic Pathway for Patients with Cognitive Impairment: Real-World Data from Seven European and North American Countries.

Ritchie CW, Black CM, Khandker RK, Wood R, Jones E, Hu X, Ambegaonkar BM.

J Alzheimers Dis. 2018;62(1):457-466. doi: 10.3233/JAD-170864.

PMID:
29439347
14.

Contemporary data on treatment practices for low-density lipoprotein cholesterol in 3867 patients who had suffered an acute coronary syndrome across the world.

Gitt AK, Lautsch D, Ferrières J, De Ferrari GM, Vyas A, Baxter CA, Bash LD, Ashton V, Horack M, Almahmeed W, Chiang FT, Poh KK, Brudi P, Ambegaonkar B.

Data Brief. 2017 Nov 14;16:369-375. doi: 10.1016/j.dib.2017.11.034. eCollection 2018 Feb.

15.

Economic Burden, Mortality, and Institutionalization in Patients Newly Diagnosed with Alzheimer's Disease.

Black CM, Fillit H, Xie L, Hu X, Kariburyo MF, Ambegaonkar BM, Baser O, Yuce H, Khandker RK.

J Alzheimers Dis. 2018;61(1):185-193. doi: 10.3233/JAD-170518.

PMID:
29103033
16.

Modelling total coronary heart disease burden and long-term benefit of cholesterol lowering in middle aged men with and without a history of cardiovascular disease.

Packard CJ, Young R, Ross K, Ford I, Ambegaonkar BM, Brudi P, McCowan C.

Eur Heart J Qual Care Clin Outcomes. 2017 Oct 1;3(4):281-288. doi: 10.1093/ehjqcco/qcx012.

17.

Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II.

Gitt AK, Lautsch D, Ferrières J, De Ferrari GM, Vyas A, Baxter CA, Bash LD, Ashton V, Horack M, Almahmeed W, Chiang FT, Poh KK, Brudi P, Ambegaonkar B.

Atherosclerosis. 2017 Nov;266:158-166. doi: 10.1016/j.atherosclerosis.2017.08.013. Epub 2017 Aug 21.

PMID:
29028484
18.

Suboptimal achievement of low-density lipoprotein cholesterol targets in French patients with coronary heart disease. Contemporary data from the DYSIS II ACS/CHD study.

Ferrières J, Rouyer MV, Lautsch D, Ashton V, Ambegaonkar BM, Brudi P, Gitt AK; Dyslipidemia International Study (DYSIS) II France Study Group.

Arch Cardiovasc Dis. 2017 Mar;110(3):167-178. doi: 10.1016/j.acvd.2016.11.004. Epub 2017 Feb 13.

19.

Contemporary data on low-density lipoprotein cholesterol target value attainment and distance to target in a cohort of 57,885 statin-treated patients by country and region across the world.

Gitt AK, Lautsch D, Ferrieres J, Kastelein J, Drexel H, Horack M, Brudi P, Vanneste B, Bramlage P, Chazelle F, Sazonov V, Ambegaonkar B.

Data Brief. 2016 Sep 29;9:616-620. eCollection 2016 Dec.

20.

Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients.

Gitt AK, Lautsch D, Ferrieres J, Kastelein J, Drexel H, Horack M, Brudi P, Vanneste B, Bramlage P, Chazelle F, Sazonov V, Ambegaonkar B.

Atherosclerosis. 2016 Dec;255:200-209. doi: 10.1016/j.atherosclerosis.2016.09.004. Epub 2016 Sep 9.

PMID:
27667299
21.

Improvement in achievement of lipid targets in France: Comparison of data from coronary patients in the DYSIS and DYSIS II studies.

Ferrières J, Rouyer MV, Lautsch D, Ambegaonkar BM, Horack M, Brudi P, Gitt AK; Dyslipidemia International Study (DYSIS) and DYSIS II Study Group.

Int J Cardiol. 2016 Nov 1;222:793-794. doi: 10.1016/j.ijcard.2016.08.084. Epub 2016 Aug 5. No abstract available.

PMID:
27521563
22.

Prevalence of potential familial hypercholesteremia (FH) in 54,811 statin-treated patients in clinical practice.

Catapano AL, Lautsch D, Tokgözoglu L, Ferrieres J, Horack M, Farnier M, Toth PP, Brudi P, Tomassini JE, Ambegaonkar B, Gitt AK.

Atherosclerosis. 2016 Sep;252:1-8. doi: 10.1016/j.atherosclerosis.2016.07.007. Epub 2016 Jul 14.

23.

Cost-effectiveness of adding ezetimibe to atorvastatin vs switching to rosuvastatin therapy in Portugal.

Laires PA, Ejzykowicz F, Hsu TY, Ambegaonkar B, Davies G.

J Med Econ. 2015;18(8):565-72. doi: 10.3111/13696998.2015.1031794. Epub 2015 Apr 10.

PMID:
25788039
24.

Impact of Switching From High-Efficacy Lipid-Lowering Therapies to Generic Simvastatin on LDL-C Levels and LDL-C Goal Attainment Among High-Risk Primary and Secondary Prevention Populations in the United Kingdom.

Cao X, Ejzykowicz F, Ramey DR, Sajjan S, Ambegaonkar BM, Mavros P, Tunceli K.

Clin Ther. 2015 Apr 1;37(4):804-15. doi: 10.1016/j.clinthera.2014.12.019. Epub 2015 Jan 24.

PMID:
25626487
25.

Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis.

Ambegaonkar BM, Tipping D, Polis AB, Tomassini JE, Tershakovec AM.

Atherosclerosis. 2014 Dec;237(2):829-37. doi: 10.1016/j.atherosclerosis.2014.10.105. Epub 2014 Nov 4.

PMID:
25463129
26.

Factors influencing dyslipidemia in statin-treated patients in Lebanon and Jordan: results of the Dyslipidemia International Study.

Azar ST, Hantash HA, Jambart S, El-Zaheri MM, Rachoin R, Chalfoun A, Lahoud L, Okkeh O, Bramlage P, Brudi P, Ambegaonkar BM.

Vasc Health Risk Manag. 2014 May 7;10:225-35. doi: 10.2147/VHRM.S57194. eCollection 2014.

27.

Prevalence and management of chronic kidney disease in primary care patients in the UK.

Jameson K, Jick S, Hagberg KW, Ambegaonkar B, Giles A, O'Donoghue D.

Int J Clin Pract. 2014 Sep;68(9):1110-21. doi: 10.1111/ijcp.12454. Epub 2014 May 23.

PMID:
24852335
28.

Prevalence of lipid abnormalities and attainment of normal lipid levels among patients with dyslipidaemia: a pooled analysis of observational studies from five Asian countries.

Unniachan S, Bash LD, Khovidhunkit W, Sri RZ, Vicaldo E, Recto C 2nd, Ambegaonkar BM.

Int J Clin Pract. 2014 Aug;68(8):1010-9. doi: 10.1111/ijcp.12407. Epub 2014 Mar 25.

PMID:
24666791
29.

Results of the Dyslipidemia International Study (DYSIS)-Middle East: clinical perspective on the prevalence and characteristics of lipid abnormalities in the setting of chronic statin treatment.

Al Sifri SN, Almahmeed W, Azar S, Okkeh O, Bramlage P, Jünger C, Halawa I, Ambegaonkar B, Wajih S, Brudi P.

PLoS One. 2014 Jan 6;9(1):e84350. doi: 10.1371/journal.pone.0084350. eCollection 2014.

30.

Prevalence of mixed dyslipidemia among Australian patients undergoing lipid-modifying therapy.

Colquhoun D, Chirovsky D, Sazonov V, Cui YA, Ambegaonkar B.

Exp Clin Cardiol. 2013 Winter;18(1):e32-6.

31.

Attainment of normal lipid levels among high cardiovascular risk patients: pooled analysis of observational studies from the United Kingdom, Sweden, Spain and Canada.

Ambegaonkar BM, Bash LD, Chirovsky DR, Jameson K, Grant S, Nocea G, Pettersson B, Sazonov V.

Eur J Intern Med. 2013 Oct;24(7):656-63. doi: 10.1016/j.ejim.2013.07.005. Epub 2013 Aug 13.

PMID:
23953848
32.

Impact of lipid-lowering therapy on the prevalence of dyslipidaemia in patients at high-risk of cardiovascular events in UK primary care - a retrospective database study.

Jameson K, Amber V, D'Oca K, Mills D, Giles A, Ambegaonkar B.

Int J Clin Pract. 2013 Dec;67(12):1228-37. doi: 10.1111/ijcp.12238. Epub 2013 Aug 14.

33.

Time to initiation of oral antihyperglycemic and statin therapy in previously untreated patients with type 2 diabetes in the United States.

Sun P, Tunceli K, Zhang Q, Seck T, Iglay K, Davies MJ, Ambegaonkar B, Radican L.

Curr Med Res Opin. 2013 Jul;29(7):801-6. doi: 10.1185/03007995.2013.800473. Epub 2013 May 10.

PMID:
23621515
34.

Attainment of goal and normalized lipid levels with lipid-modifying therapy in Malaysia.

Hsu TY, Chirovsky D, Moy FM, Ambegaonkar BM.

Clin Ther. 2013 Apr;35(4):450-60. doi: 10.1016/j.clinthera.2013.02.004. Epub 2013 Mar 5.

PMID:
23481458
35.

Association of a reduction in low-density lipoprotein cholesterol with incident cardiovascular and cerebrovascular events among people with type 2 diabetes mellitus.

Li L, Ambegaonkar BM, Reckless JP, Jick S.

Eur J Prev Cardiol. 2014 Jul;21(7):855-65. doi: 10.1177/2047487313481752. Epub 2013 Mar 4.

PMID:
23460659
36.

Mixed dyslipidemias in primary care patients in France.

Laforest L, Ambegaonkar BM, Souchet T, Sazonov V, Van Ganse E.

Vasc Health Risk Manag. 2012;8:247-54. doi: 10.2147/VHRM.S27668. Epub 2012 Apr 19.

37.

Attainment of normal lipid levels among patients on lipid-modifying therapy in Hong Kong.

Ambegaonkar B, Chirovsky D, Tse HF, Lau YK, Tomlinson B, Li SK, Yue CS, Wong TH, Choi MC, Tunggal P, Sazonov V.

Adv Ther. 2012 May;29(5):427-41. doi: 10.1007/s12325-012-0017-9. Epub 2012 May 3.

PMID:
22562782
38.

Changes in HDL cholesterol and cardiovascular outcomes after lipid modification therapy.

Ray K, Wainwright NW, Visser L, Witteman J, Breteler M, Ambegaonkar B, Hofman A, Stricker B, Wareham N, Khaw KT, Sandhu M.

Heart. 2012 May;98(10):780-5. doi: 10.1136/heartjnl-2011-301405. Epub 2012 Mar 24.

39.

Prevalence of dyslipidemia and goal attainment after initiating lipid-modifying therapy: a Thai multicenter study.

Khovidhunkit W, Silaruks S, Chaithiraphan V, Ongphiphadhanakul B, Sritara P, Nimitphong H, Benjanuwattra T, Ambegaonkar BM.

Angiology. 2012 Oct;63(7):528-34. doi: 10.1177/0003319711432451. Epub 2012 Jan 5.

PMID:
22222187
40.

Association between extended-release niacin treatment and glycemic control in patients with type 2 diabetes mellitus: analysis of an administrative-claims database.

Ambegaonkar BM, Wentworth C, Allen C, Sazonov V.

Metabolism. 2011 Jul;60(7):1038-44. doi: 10.1016/j.metabol.2010.11.001. Epub 2010 Dec 24.

PMID:
21185576
41.

Prevalence of lipid abnormalities before and after introduction of lipid modifying therapy among Swedish patients with dyslipidemia (PRIMULA).

Pettersson B, Ambegaonkar B, Sazonov V, Martinell M, Stålhammar J, Wändell P.

BMC Public Health. 2010 Nov 29;10:737. doi: 10.1186/1471-2458-10-737.

42.

The effects of isolated versus multiple lipid disorders on resource utilization among metabolic syndrome patients with lipid abnormalities despite Lipid-modifying treatment.

Ambegaonkar B, Chirovsky D, Wu W, Colclough H, Milligan G, Sazonov V.

Cardiology. 2010;117(2):96-104. doi: 10.1159/000318022. Epub 2010 Oct 12.

PMID:
20938176
43.

Utilization patterns of extended-release niacin in Canada: analysis of an administrative claims database.

Dorais M, Chirovsky D, Ambegaonkar B, Sazonov V, Davies G, Grant S, Lelorier J.

Can J Cardiol. 2010 Aug-Sep;26(7):e229-35.

44.

Frequency of obtaining national cholesterol education program adult treatment panel III goals for all major serum lipoproteins after initiation of lipid altering therapy.

Nichols GA, Ambegaonkar BM, Sazonov V, Brown JB.

Am J Cardiol. 2009 Dec 15;104(12):1689-94. doi: 10.1016/j.amjcard.2009.07.050.

PMID:
19962476
45.

Frequency of diagnosis and treatment of allergic rhinitis among adults with asthma in Germany, France, and the UK: National Health and Wellness Survey.

Sazonov V, Ambegaonkar BM, Bolge SC, Radican L, Fan T, Taylor SD.

Curr Med Res Opin. 2009 Jul;25(7):1721-6. doi: 10.1185/03007990902915061.

PMID:
19505203
46.

Patients' experiences of niacin-induced flushing in clinical practice: a structured telephone interview.

Kamal-Bahl S, Watson DJ, Ambegaonkar BM.

Clin Ther. 2009 Jan;31(1):130-40. doi: 10.1016/j.clinthera.2009.01.011.

PMID:
19243714
47.

The impact of anemia on quality of life and healthcare resource utilization in patients with HIV/AIDS receiving antiretroviral therapy.

Bolge SC, Mody S, Ambegaonkar BM, McDonnell DD, Zilberberg MD.

Curr Med Res Opin. 2007 Apr;23(4):803-10.

PMID:
17407637
48.

Treatment satisfaction with a transdermal contraceptive patch or oral contraceptives.

Wan GJ, Barnowski CE, Ambegaonkar BM, Bolge SC, McDonnell DD.

Contraception. 2007 Apr;75(4):281-4. Epub 2007 Feb 16.

PMID:
17362706

Supplemental Content

Loading ...
Support Center